The Drug Pricing Conundrum: Are Patents to Blame for High Drug Prices*

The Drug Pricing Conundrum: Are Patents to Blame for High Drug Prices*

View Session Speakers

At a time when the Biden Administration is attempting to blame patents for everything relating to drug prices, patents on some of the most popular drugs the world has ever seen will soon be expiring.  This panel will discuss the escalating debate over drug pricing, whether patents really are to blame for high drug prices, why the Biden Administration is threatening to “march-in“ to compel licensing of patent rights, and the FDA and FTC‘s recent efforts to delist patents from the Orange Book. The panel will also discuss what this all means for the biopharmaceutical industry, how companies and investors are likely to respond, and will question the Biden Administration‘s rationale for attempting to reduce drug prices.

Materials

• Chamber Says White House Announcement on Medicare Drug Prices Threatens Patient Access
  
• Are Patents to Blame for High Drug Prices?
• Why the Math Doesn’t Support Blaming Drug Patents for the High Cost of U.S. Healthcare
• Biden Admin and U.S. Chamber Clash Over IRA Drug Pricing Impact
• Tillis Tells Judiciary Committee That Hyper-Focus on Patents Has Led to Lack of Progress on Drug Pricing

Survey

https://www.surveymonkey.com/r/The-Drug-Pricing-Conundrum